Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Leukemia

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.leu.2401719PMID 10764143
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular Cloning: A Laboratory Manual

  2001cited by this paper
• Clonality analysis by methylation-specific PCR for the human androgen-receptor gene (HUMARA-MSP)

  2000cited by this paper
• Clonality analysis of refractory anemia with ring sideroblasts: simultaneous study of clonality and cytochemistry of bone marrow progenitors

  1999cited by this paper
• Clonality analysis of refractory anemia with ring sideroblasts: simultaneous study of clonality and cytochemistry of bone marrow progenitors(環状鉄芽球を伴う不応性貧血患者のクロナリティ解析: 骨髄前駆細胞のクロナリティと形態学的所見の同時検討)

  1999cited by this paper
• Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression.

  1998cited by this paper
• Hypermethylation of p15INK4B Gene in a Patient With Acute Myelogenous Leukemia Evolved From Paroxysmal Nocturnal Hemoglobinuria

  1998cited by this paper
• Alterations in DNA methylation: a fundamental aspect of neoplasia.

  1998cited by this paper
• Hypermethylation of p15(INK4B) gene in a patient with acute myelogenous leukemia evolved from paroxysmal nocturnal hemoglobinuria.

  1998cited by this paper
• Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies.

  1997cited by this paper
• DNA methylation changes in hematologic malignancies: biologic and clinical implications.

  1997cited by this paper
• Hypermethylation of the p15INK4B gene in myelodysplastic syndromes.

  1997cited by this paper
• Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

  1996cited by this paper
• THE ROLE OF DNA METHYLATION IN CANCER GENETICS AND EPIGENETICS

  1996cited by this paper
• The role of DNA methylation in cancer genetic and epigenetics.

  1996cited by this paper
• Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes

  1995cited by this paper
• Peripheral blood cells are predominantly chimeric of affected and normal cells in patients with paroxysmal nocturnal hemoglobinuria: simultaneous investigation on clonality and expression of glycophosphatidylinositol-anchored proteins

  1994cited by this paper
• Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations.

  1994cited by this paper
• Peripheral blood cells are predominantly chimeric of affected and normal cells in patients with paroxysmal nocturnal hemoglobinuria: simultaneous investigation on clonality and expression of glycophosphatidylinositol-anchored proteins.

  1994cited by this paper
• Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes.

  1994cited by this paper
• Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations.

  1994cited by this paper
• Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis.

  1993cited by this paper
• Clonality in myelodysplastic syndromes: demonstration of pluripotent stem cell origin using X‐linked restriction fragment length polymorphisms

  1993cited by this paper
• A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands.

  1992cited by this paper
• Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation.

  1992cited by this paper
• Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction.

  1991cited by this paper
• Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin.

  1989cited by this paper
• Correlation of bone marrow colony growth in the myelodysplastic syndromes with the FAB classification and the Bournemouth score.

  1989cited by this paper

• DNA methyltransferase inhibitors in hematological malignancies and solid tumors

  2025cites this paper
• Can peripheral blood provide good DNA methylation biomarkers in myelodysplastic syndrome?

  2021cites this paper
• Realgar (α-As4S4) Treats Myelodysplastic Syndromes through Reducing DNA Hypermethylation

  2020cites this paper
• Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia

  2019cites this paper
• Role of p15(INK4B) Methylation in Patients With Myelodysplastic Syndromes: A Systematic Meta-Analysis.

  2019cites this paper
• 15 p 15 INK 4 b , a Tumor Suppressor in Acute Myeloid Leukemia

  2017cites this paper
• Targeting the Sonic Hedgehog-Gli1 Pathway as a Potential New Therapeutic Strategy for Myelodysplastic Syndromes

  2015cites this paper
• Epigenetic inhibitors.

  2015cites this paper
• 5-Azacytidine/5-Azacitidine.

  2014cites this paper
• The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia.

  2014cites this paper
• hematopoietic malignancies -deoxycytidine (decitabine) in ' hypomethylating agent 5-aza-2 Phase 1 study of low-dose prolonged exposure schedules of the

  2013cites this paper
• Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.

  2013cites this paper
• leukemia higher risk myelodysplastic syndrome and chronic myelomonocytic Results of a randomized study of three schedules of low-dose decitabine in

  2013cites this paper
• Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine

  2013cites this paper
• CDKN 2 B ( cyclin-dependent kinase inhibitor 2 B ( p 15 , inhibits CDK 4 ) )

  2012cites this paper
• p15Ink4b Loss Impairs the Maturation and Activation of Conventional Dendritic Cells

  2012cites this paper
• Identification of genetic aberrations in myelodysplastic syndromes

  2012cites this paper
• p15INK4b, a Tumor Suppressor in Acute Myeloid Leukemia

  2011cites this paper
• [Tumor stem cell research - basis and challenge for diagnosis and therapy].

  2010cites this paper
• Myelodysplastic Syndromes (MDS)

  2010cites this paper
• Epigenetic changes in the myelodysplastic syndrome.

  2010cites this paper
• 5-Azacytidine/Azacitidine.

  2010cites this paper
• Molecular Pathogenesis of Myelodysplastic Syndromes

  2010cites this paper
• Tumor-Stammzellforschung – Basis und Herausforderung für Diagnostik und Therapie

  2010cites this paper
• Epigenetic alterations as cancer diagnostic, prognostic, and predictive biomarkers.

  2010cites this paper
• A limited number of 5-azacitidine cycles can be effective treatment in MDS

  2009cites this paper
• A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia

  2008cites this paper
• Biological Study of MG 98 , an Oligodeoxynucleotide Antisense to DNAMethyltransferase 1 , in Patients with High-RiskMyelodysplasia andAcuteMyeloid Leukemia

  2008cites this paper
• Loss of the tumor suppressor p15Ink4b enhances myeloid progenitor formation from common myeloid progenitors.

  2007cites this paper
• Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

  2007cites this paper
• Myelodysplastic syndromes, aging, and age: Correlations, common mechanisms, and clinical implications

  2007cites this paper
• Decitabine--bedside to bench.

  2007cites this paper
• Drug resistance and methylation in myelodysplastic syndrome.

  2007cites this paper
• Long‐term follow‐up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

  2006cites this paper
• Novel agents for the management of myelodysplastic syndromes.

  2006cites this paper
• Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early‐stage patients

  2006cites this paper
• Methylation and myelodysplastic syndromes: when and where?

  2006cites this paper
• Low-dose decitabine and high-risk MDS.

  2006cites this paper
• Epigenetics and chronic lymphocytic leukemia

  2006cites this paper
• DNA Methyltransferase Inhibitors

  2005cites this paper
• Myelodysplastic syndromes: clinicopathologic features, pathobiology, and molecular pathogenesis.

  2005cites this paper
• Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity.

  2005cites this paper
• Management of patients with higher risk myelodysplastic syndromes.

  2005cites this paper
• Promoter methylation as a prognostic factor in MDS 25

  2005cites this paper
• An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients

  2005cites this paper
• Decitabine in acute myeloid leukemia.

  2005cites this paper
• Role of epigenetic changes in hematological malignancies

  2004cites this paper
• Novel therapies for myelodysplastic syndromes

  2004cites this paper
• Epigenetic Inactivation of Tumor Suppressor Genes in Hematologic Malignancies

  2004cites this paper
• Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

  2004cites this paper
• Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia

  2003cites this paper
• Epigenetic targets in hematopoietic malignancies

  2003cites this paper
• Gene silencing of the p15/INK4B cell-cycle inhibitor by hypermethylation: an early or later epigenetic alteration in myelodysplastic syndromes?

  2003cites this paper
• Expression levels of DNA methyltransferase genes do not correlate with p15INK4B gene methylation in myelodysplastic syndromes

  2003cites this paper
• Aberrant methylation and impaired expression of the p15INK4b cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML)

  2003cites this paper
• Important features of myelodysplastic syndrome

  2002cites this paper
• Transplante de medula óssea nas síndromes mielodisplásicas

  2002cites this paper
• Selective inhibition of DNA methyltransferase enzymes as a novel strategy for cancer treatment.

  2002cites this paper
• The impact of biology on the treatment of secondary AML.

  2001cites this paper
• Loss of heterozygosity and heterogeneity of its appearance and persisting in the course of acute myeloid leukemia and myelodysplastic syndromes.

  2001cites this paper
• Relationship between methylation of the p15 gene and ectopic expression of the EVI-1 gene in myelodysplastic syndromes (MDS).

  2001cites this paper
• Cancer Management and Research Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress the Role of Azacitidine in the Management of Myelodysplastic Syndromes (mds)

  year unknowncites this paper